TickerTalks
Browse all tickers →
TickerTalks›$PRE
PRPRE

Prenetics Global Limited

$PRE·$316M·Household & Personal Products·Consumer Defensive
$18.65+0.7%YTD+33.1%1Y+16.8%
Price updated 14m ago·X counts updated 8d ago
PRPRE
$PREPrenetics Global Limited
$18.65+0.70%19 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $PRE on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

19X posts · last 7 days
Oct 1Oct 11

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $PRE — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventAcceleratingAI verdict · as of 2026-10-03

The move is getting stronger, with heavier trading behind it.

A consumer-health pivot that is actually working — IM8 driving 163% revenue growth and the CEO/CFO put a million dollars in at these prices.

Prenetics Global is in the middle of a real pivot — the IM8 longevity supplement line plus CircleDNA genetic testing have replaced the old COVID-testing identity, and the operating cadence is backing the story.

  • Q2 revenue of $46.5M was up 163% YoY after Q1 at +108%, Q4 at +249%, and Q3 at +203% — four consecutive quarters of triple-digit growth makes the IM8 ramp a durable trend, not a one-print surprise.
  • IM8's CEO and CFO bought $1.0M of PRE shares in the open market after the Q2 release (August 26 news item), which is the only insider signal that matters when you are trying to validate a consumer-brand pivot.
  • Sell-side revenue steps from $224M in 2026 to $407M in 2027 to $554M in 2028 with EPS crossing to breakeven in 2028 and $1.38 positive in 2029 — the current $343M market cap at 1.5x 2027 revenue is reasonable if the ramp holds.

At $20.17 the stock is now at 55% of the 52-week range with a 8% pullback on the day's print — the November 9 earnings is the next hard confirmation that IM8 marketing spend is still returning revenue growth above cost.

What to watch: November 9 Q3 earnings and whether triple-digit revenue growth holds; IM8 unit economics and customer-acquisition-cost disclosure; any further open-market purchases from the IM8 or Prenetics parent executives.

On the calendar: Q3 earnings scheduled 2026-11-09

Read the AI verdict on $PRE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Genomics and diagnostics company offering consumer DNA testing, cancer screening, and preventive health monitoring, primarily serving Asian markets.

Industry overviewAI analysisGenerated by AI from underlying data

Where Household & Personal Products sits in its cycle right now — and what that implies for $PRE.

Household & Personal Products · Consumer Defensive

No material change from last week — Mass beauty is outperforming prestige as China travel-retail headwinds persist for Estee Lauder.

What this means for $PRE

Neutral — Genomics and diagnostics company offering consumer DNA testing, cancer screening, and preventive health monitoring, primarily serving Asian markets.

Industry benchmark

12-name peer basket
+13.7%YTD
-2.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-6.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-42.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-35.2%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-7.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-49.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
62.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 18, 2026$-0.53$-0.84+36.9%
Q1 2026Jun 10, 2026$-1.36$-0.49-177.6%
Q4 2025Feb 18, 2026$-1.75$-0.41-326.8%
Q3 2025Nov 10, 2025$-0.41$-0.55+25.5%
Next earningsMon, Nov 9·consensus EPS $-0.85

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$46.5M+162.9%65.0%-47.1%$-0.52$0
Q1 FY26$36.0M+107.7%64.8%-27.0%$-1.36$-12.1M
Q4 FY25$36.6M+248.6%59.5%-33.9%$-1.75$-22.0M
Q3 FY25$23.6M+202.8%59.5%-26.2%$-0.53$0

Forward consensus

5-year forecast · up to 6 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$223.6M$220.6M – $226.2M-$3.57-$4.25 – -$2.606
FY27$407.0M$396.3M – $413.5M-$1.78-$6.81 – $2.304
FY28$553.7M$525.6M – $578.7M-$0.12-$2.20 – $2.125
FY29$695.3M$678.7M – $708.2M$1.38$1.34 – $1.412
FY30$781.0M$762.4M – $795.4M$2.62$2.54 – $2.682

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.45%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-16.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-5.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β0.255-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyAug 25Brian J RosinCFO5.1K sh$116KBuyAug 24Brian J RosinCFO18.0K sh$381KBuyAug 24Yeung Danny Sheng WuCEO17.2K sh$365KBuyAug 20Yeung Danny Sheng WuCEO7.5K sh$137K
+ 13 other (9 exempts · 3 awards · 1 other) in window

See when $PRE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsAug 263
AI summary

Primerica (PRE) filed a Form 3 for Caroline S. Levy, newly appointed director. Levy was granted 7,595 Restricted Stock Units that vest in 2033. No direct share purchases were reported.

3New insider — initial holdingsAug 123
AI summary

Primerica (PRE) filed a Form 3 for Stephen Hoi Chun Lo, a newly appointed officer. Lo reported zero beneficial ownership of Primerica securities as of the filing date. This is a routine initial ownership statement.

3New insider — initial holdingsJul 103
3New insider — initial holdingsJun 153
3/ANew insider — initial holdingsMay 283/A
+ 23 other (14 6-Ks · 3 F-1/As · 3 20-F/As · 1 S-8) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

CAMTEK PRE-ANNOUNCES RECORD Q3 REVENUES ABOVE GUIDANCE; PROVIDES RECORD Q4 GUIDANCE AND INITIAL REVENUE OUTLOOK FOR 2027prnewswire.com·5d agoSPECTRUM COMMUNITY SOLUTIONS TO BRING PRE-INSTALLED INTERNET AND WIFI TO SILVERWOOD'S NEW COMMUNITY, SILVERWOOD, IN HESPERIA, CALIF.prnewswire.com·12d agoIs Prenetics Global Ltd (PRE) a Bargain After 8.1% Drop? GF Value Says Undervaluedgurufocus.com·17d agoU.S. VEHICLE SALES UNLIKELY TO REGAIN PRE-PANDEMIC LEVELS THIS DECADE, MOBILITY GLOBAL FORECAST SHOWSprnewswire.com·21d agoPrenetics Global Limited (NASDAQ:PRE) Receives Consensus Recommendation of “Moderate Buy” from Analystsdefenseworld.net·24d ago

More in Household & Personal Products

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$CL$PG$ELF$EL$KMB$CLX$UL$COTY
Voices on X · last 7 days

No standout posts about $PRE on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport